New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
04:55 EDTCFN, CFN, CFN, JAZZ, JAZZ, JAZZ, RMD, RMD, RMD, VNDA, VNDA, VNDA, XNPT, XNPT, XNPTAssociated Professional Sleep Societies to hold annual meeting
28th Annual SLEEP Meeting is being held in Minneapolis on May 31-June 4.
News For CFN;JAZZ;RMD;VNDA;XNPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
14:32 EDTJAZZPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
08:12 EDTVNDAVanda names Tom Gibbs as SVP and Chief Commercial OfficerBristol-Myers
Subscribe for More Information
April 17, 2015
10:56 EDTRMDResMed price target raised to $82 from $69 at Piper Jaffray
Subscribe for More Information
April 13, 2015
17:48 EDTVNDAVanda announces Feb. 29, 2016 trial date for Fanapt patent cases
Vanda Pharmaceuticals announced a February 29, 2016 trial date for two pending cases against Roxane Laboratories regarding Roxane's submission of an ANDA to obtain approval to make and sell generic Fanapt. The two cases have been consolidated by agreement of the parties and are scheduled to be tried together in a four-day bench trial beginning on February 29, 2016. In C.A. No. 14-757-GMS, Vanda is asserting U.S. Patent No. 8,586,610 ('610 patent), covering methods of treating schizophrenia by administering Fanapt to certain patients, while in C.A. No. 13-1973-GMS, Vanda is asserting the U.S. composition of matter patent for Fanapt, U.S. Patent No. RE39,198. Both patents are listed in the FDA publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The '610 patent expires November 2027 and the RE'198 patent expires November 2016.
April 10, 2015
17:35 EDTVNDABaker Bros. Advisors lowers passive stake in Vanda to 4.2% from 10.8%
Subscribe for More Information
April 9, 2015
09:16 EDTVNDAVanda's Fanapt patent listed in FDA Orange Book
Subscribe for More Information
April 7, 2015
10:10 EDTJAZZJazz patent on Xyrem latest to be challenged by Kyle Bass
Subscribe for More Information
10:05 EDTRMDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Carnival (CCL) upgraded to Outperform from Market Perform at Wells Fargo... Crown Castle (CCI) upgraded to Buy from Hold at Evercore ISI... Ctrip.com (CTRP) upgraded to Overweight from Neutral at Piper Jaffray... Demandware (DWRE) upgraded to Conviction Buy from Buy at Goldman... FirstEnergy (FE) upgraded at BofA/Merrill... Frontier Communications (FTR) upgraded to Neutral from Underperform at DA Davidson... JPMorgan (JPM) upgraded to Outperform from Market Perform at Bernstein... Pattern Energy (PEGI) upgraded to Outperform from Market Perform at Raymond James... Ralph Lauren (RL) upgraded to Buy from Outperform at CLSA... ResMed (RMD) upgraded to Outperform from Neutral at Credit Suisse... Ryanair (RYAAY) upgraded to Overweight from Neutral at JPMorgan... Splunk (SPLK) upgraded to Overweight from Neutral at Piper Jaffray... Total (TOT) upgraded at RBC Capital... Verifone (PAY) upgraded to Buy from Hold at Stifel... XL Group (XL) upgraded to Buy from Neutral at UBS.
08:08 EDTRMDResMed upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use